Search for dissertations about: "Imatinib"
Showing result 11 - 15 of 55 swedish dissertations containing the word Imatinib.
-
11. Studies of leukotriene C4 synthase expression and regulation in chronic myeloid leukaemia
Abstract : Leukotriene (LT) C4 is generated through conjugation of LTA4 with glutathione by the actions of leukotriene C4 synthase (LTC4S). This biologically potent mediator of asthma and inflammation has also been suggested to play a regulatory role in human myelopoiesis and is overproduced by blood and bone marrow cells from patients with chronic myeloid leukaemia (CML). READ MORE
-
12. Anti-Diabetic and Beta-Cell Protective Actions of Imatinib Mesylate
Abstract : Type 1 diabetes is a disease resulting from the progressive immune-mediated destruction of insulin producing β-cells. In order to understand more about diabetes we need to understand the mechanisms governing β-cell death.The leukemia drug Gleevec is a tyrosine kinase inhibitor that targets c-Abl. READ MORE
-
13. Molecular mechanisms of imatinib resistance in gastrointestinal stromal tumor with focus on microRNAs
Abstract : Gastrointestinal stromal tumor (GIST) is mainly initialized by mutations in receptor tyrosine kinase genes KIT or PDGFRA. The development of imatinib, a small molecule inhibitor that targets these tyrosine kinase receptors, remarkably improved patient outcome. READ MORE
-
14. Chronic myeloid leukemia-clinical, experimental and health economic studies with special reference to imatinib treatment
Abstract : CML is a malignant disease that originates in the bone marrow stem cell, carrying the Philadelphia chromosome with the BCR-ABL fusion gene. This gene translates into an active tyrosine kinase, Bcr-Abl, affecting hematopoiesis, particularly resulting in increased numbers of white blood cells in the peripheral blood. READ MORE
-
15. Influence of CYP3A enzymes and ABC transporters on the activity of tyrosine kinase inhibitors in chronic myeloid leukemia
Abstract : The introduction of imatinib, a tyrosine kinase inhibitor (TKI), in the treatment of chronic myeloid leukemia (CML) was a major break-through and the first drug that was successfully designed to target the specific mechanism of a malignant disease. Imatinib still remains as the standard treatment of newly diagnosed CML patients although a second generation of TKIs has also been approved for first-line CML treatment. READ MORE
